The Patent Finder
US

Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof

US 11,472,858 In force
OverviewFamilyAssignmentsSources & methods

Term ends Feb 8, 2038 · Low confidence

Filed Jun 21, 2021 as application 17/352,915 · Granted Oct 18, 2022
USPTO first gave this application the number US 11,339,200 and withdrew it before it issued. That number now leads here.
Base term, 20 years from filing
Today
20 years from filing
2018 2038
Clock starts
Feb 8, 2018
Term ends
Feb 8, 2038
Granted
Oct 18, 2022
base term fee events Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 11,066,457, to Feb 8, 2038. The term already ends on or before that date, so the cap shortened nothing.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: Low. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Feb 8, 2018, when application PCT/CN2018/075867, the earliest non-provisional in its chain, was filed (this one was filed Jun 21, 2021); a parent in its chain could not be resolved (the next row)Feb 8, 2038High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 11,066,457)resolves to Feb 8, 2038, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 3 maintenance fees paidIn forceHigh confidence
Further caveats on recordThe record names parents not resolved: 16484482Low confidence overallLow confidence
Computed term endThe steps above, in orderFeb 8, 2038Low confidence

This family

US 11,066,457In force
Feb 2038
Feb 2038
US 11,472,858this patent
Feb 2038
Feb 2038
US 11,618,778In force
Feb 2038
Feb 2038
US 11,608,369In force
Feb 2038
Feb 2038
US 12,583,903In force
Feb 2038
Feb 2038
US 12,747,279In force
Feb 2038
Feb 2038
Application 18/263,050Pending
not computed
not computed
7 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Aug 19, 2021
Reel 57233, frame 503
Yao, Yihong; Huang, Jiaqi; Zhu, Shigui; Zhu, Wei; Yao, Xin; Li, Zhiyuan; Zhang, Li; Zhu, Lin; Ma, Anyun; Wei, Yutian; Li, Yanfeng; Wang, Qingxia; He, JiapingCellular Biomedicine Group (Shanghai) Ltd.; Cellular Biomedicine Group (Wuxi) Ltd.Assignment of Assignor's Interest
Aug 19, 2021
reel/frame not recorded
He, Jiaping; Huang, Jiaqi; Li, Yanfeng; Li, Zhiyuan; Ma, Anyun; Wang, Qingxia; Wei, Yutian; Yao, Xin; Yao, Yihong; Zhang, Li; Zhu, Lin; Zhu, Shigui; Zhu, WeiCellular Biomedicine Group (Shanghai) Ltd.Assignment of Assignor's Interest
Aug 19, 2021
reel/frame not recorded
He, Jiaping; Huang, Jiaqi; Li, Yanfeng; Li, Zhiyuan; Ma, Anyun; Wang, Qingxia; Wei, Yutian; Yao, Xin; Yao, Yihong; Zhang, Li; Zhu, Lin; Zhu, Shigui; Zhu, WeiCellular Biomedicine Group (Wuxi) Ltd.Assignment of Assignor's Interest
Aug 20, 2021
Reel 57236, frame 919
Cellular Biomedicine Group (Shanghai) Ltd.Cellular Biomedicine Group HK LimitedAssignment of Assignor's Interest
Aug 20, 2021
Reel 57236, frame 979
Cellular Biomedicine Group (Wuxi) Ltd.Cellular Biomedicine Group HK LimitedAssignment of Assignor's Interest
Dec 15, 2022
Reel 62105, frame 405
Cellular Biomedicine Group HK Ltd.Cellular Biomedicine Group Inc.Assignment of Assignor's Interest
Jan 19, 2024
Reel 66356, frame 108
Cellular Biomedicine Group, Inc.Abelzeta Inc.Change of Name

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited